Ocular Therapeutix Insider Filing Reveals Large Equity Grant to New CBO
Rhea-AI Filing Summary
Ocular Therapeutix (OCUL) filed a Form 3 disclosing the initial beneficial ownership of its newly appointed Chief Business Officer, Namrata Saroj. The filing reports direct ownership of 200,000 unvested restricted stock units (RSUs) that will vest in three equal annual installments beginning on the first anniversary of her start date.
Derivative holdings include 466,000 stock options spread across three grants: 50,000 options already fully vested at an exercise price of $9.95 expiring 02/27/2034; 100,000 options granted 02/28/2024 at $9.95 vesting 1/48 monthly after an initial one-year cliff; and 316,000 options granted 11/04/2024 at $10.27 with similar four-year vesting. All holdings are reported as direct ownership.
The filing is routine, conveys no operational or financial performance data, and does not imply the insider owns more than 10 % of outstanding shares.
Positive
- Alignment of interests: Granting 200,000 RSUs and 466,000 options ties the new Chief Business Officer’s compensation to OCUL’s long-term share performance.
Negative
- Potential dilution: If all RSUs vest and options are exercised, an additional 666,000 shares could be added to OCUL’s share count over time.
Insights
TL;DR: Routine Form 3; new CBO owns 200k RSUs and 466k options—minimal immediate impact, positive alignment signal.
This initial insider filing establishes Namrata Saroj as a Section 16 officer with direct exposure to 666,000 share-equivalent instruments. While the absolute stake is modest relative to OCUL’s float, the mix of time-based RSUs and long-dated, out-of-the-money options aligns her incentives with long-term shareholder value. No change to capital structure occurs today; dilution only materializes upon future vesting or exercise. Investors should view the disclosure as neutral from a valuation standpoint but note the governance signal of equity-based compensation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes 200,000 restricted stock units ("RSUs") remaining unvested pursuant to an award of 200,000 RSUs granted under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation") on November 4, 2024. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the reporting person's first date of employment and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. This option is fully vested and exercisable. This option was granted on February 28, 2024 and vests over four years, with 1/4 of the shares underlying the option having vested on February 28, 2025 and 1/48 of the shares vesting monthly thereafter. This option was granted on November 4, 2024 and vests over four years, with 1/4 of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and 1/48 of the shares vesting monthly thereafter.
